Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Immune cell dynamics following rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HWHamish WalkerPAPhilippe ArmandRMReid W. Merryman

Discussion

Loading...

Member takes

Overview

Multicenter trial shows promising response rates and immune changes with first-line rituximab and epcoritamab treatment for high-tumor burden follicular lymphoma, highlighting cytokine release effects

Key Points

  • To evaluate immune cell dynamics following rituximab and epcoritamab in untreated patients with high-tumor burden follicular lymphoma.
  • Phase II multicenter trial conducted on patients with high-tumor burden follicular lymphoma
  • Patients received debulking treatment with rituximab followed by epcoritamab in nine cycles
  • Spectral flow cytometry analyzed T-cell and B-cell populations at multiple timepoints
  • 91% best complete metabolic response rate observed
  • Decrease in CD8+ T cells after initial treatment followed by increase in subsequent weeks
  • Changes in T-cell subpopulation associated with cytokine release syndrome were noted

Cite This Study

Walker et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d260https://doi.org/10.1182/blood-2025-1790
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial2025
  2. 2Abstract 3732: Peripheral pharmacodynamic activity of epcoritamab as monotherapy and in combination with rituximab + lenalidomide in patients with follicular lymphoma2024
  3. 3primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma2025 · 2 citations
  4. 4EPCORE FL-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy or R2 in previously untreated follicular lymphoma.2024 · 7 citations
  5. 5Abstract PO-003: Peripheral blood and tumor tissue biomarkers associated with epcoritamab response in patients with relapsed or refractory diffuse large B-cell lymphoma: Data from the dose-expansion cohort of the phase 1/2 EPCORE NHL-1 trial (NCT03625037)2024 · 2 citations